These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29436901)

  • 1. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease.
    Clarke AW; Poulton L; Shim D; Mabon D; Butt D; Pollard M; Pande V; Husten J; Lyons J; Tian C; Doyle AG
    MAbs; 2018; 10(4):664-677. PubMed ID: 29436901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Necrosis Factor-like Cytokine TL1A and Its Receptors DR3 and DcR3: Important New Factors in Mucosal Homeostasis and Inflammation.
    Siakavellas SI; Bamias G
    Inflamm Bowel Dis; 2015 Oct; 21(10):2441-52. PubMed ID: 26099067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity.
    Valatas V; Kolios G; Bamias G
    Front Immunol; 2019; 10():583. PubMed ID: 30972074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tumor necrosis factor-like cytokine 1A/death receptor 3 cytokine system in intestinal inflammation.
    Bamias G; Jia LG; Cominelli F
    Curr Opin Gastroenterol; 2013 Nov; 29(6):597-602. PubMed ID: 24100723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis.
    Solitano V; Jairath V; Ungaro F; Peyrin-Biroulet L; Danese S
    Med; 2024 May; 5(5):386-400. PubMed ID: 38574740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TL1A blocking ameliorates intestinal fibrosis in the T cell transfer model of chronic colitis in mice.
    Li H; Song J; Niu G; Zhang H; Guo J; Shih DQ; Targan SR; Zhang X
    Pathol Res Pract; 2018 Feb; 214(2):217-227. PubMed ID: 29254800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of TL1A and DR3 in autoimmune and inflammatory diseases.
    Aiba Y; Nakamura M
    Mediators Inflamm; 2013; 2013():258164. PubMed ID: 24453414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease.
    Furfaro F; Alfarone L; Gilardi D; Correale C; Allocca M; Fiorino G; Argollo M; Zilli A; Zacharopoulou E; Loy L; Roda G; Danese S
    Curr Drug Targets; 2021; 22(7):760-769. PubMed ID: 33475057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNFSF/TNFRSF cytokine gene expression in sickle cell anemia: Up-regulated TNF-like cytokine 1A (TL1A) and its decoy receptor (DcR3) in peripheral blood mononuclear cells and plasma.
    Safaya S; Alfarhan M; Sulaiman A; Alsulaiman A; Al-Ali A
    Cytokine; 2019 Nov; 123():154744. PubMed ID: 31255916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases.
    Siakavellas SI; Sfikakis PP; Bamias G
    Semin Arthritis Rheum; 2015 Aug; 45(1):1-8. PubMed ID: 25887448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrogen/deuterium exchange mass spectrometry and computational modeling reveal a discontinuous epitope of an antibody/TL1A Interaction.
    Huang RY; Krystek SR; Felix N; Graziano RF; Srinivasan M; Pashine A; Chen G
    MAbs; 2018 Jan; 10(1):95-103. PubMed ID: 29135326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum decoy receptor 3 levels are associated with the disease activity of MPO-ANCA-associated renal vasculitis.
    Maruyama H; Hirayama K; Nagai M; Ebihara I; Shimohata H; Kobayashi M
    Clin Rheumatol; 2016 Oct; 35(10):2469-76. PubMed ID: 27251675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation and nuclear localization of TNF-like cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions.
    Bamias G; Evangelou K; Vergou T; Tsimaratou K; Kaltsa G; Antoniou C; Kotsinas A; Kim S; Gorgoulis V; Stratigos AJ; Sfikakis PP
    Exp Dermatol; 2011 Sep; 20(9):725-31. PubMed ID: 21672030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Death-Domain-Receptor 3 Deletion Normalizes Inflammatory Gene Expression and Prevents Ileitis in Experimental Crohn's Disease.
    Buttó LF; Jia LG; Arseneau KO; Tamagawa H; Rodriguez-Palacios A; Li Z; De Salvo C; Pizarro TT; Bamias G; Cominelli F
    Inflamm Bowel Dis; 2019 Jan; 25(1):14-26. PubMed ID: 30295722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis.
    Bamias G; Siakavellas SI; Stamatelopoulos KS; Chryssochoou E; Papamichael C; Sfikakis PP
    Clin Immunol; 2008 Nov; 129(2):249-55. PubMed ID: 18757243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease.
    Bamias G; Martin C; Marini M; Hoang S; Mishina M; Ross WG; Sachedina MA; Friel CM; Mize J; Bickston SJ; Pizarro TT; Wei P; Cominelli F
    J Immunol; 2003 Nov; 171(9):4868-74. PubMed ID: 14568967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Directed evolution of a soluble human DR3 receptor for the inhibition of TL1A induced cytokine secretion.
    Levin I; Zaretsky M; Aharoni A
    PLoS One; 2017; 12(3):e0173460. PubMed ID: 28278297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum and synovial fluid levels of tumor necrosis factor-like ligand 1A and decoy receptor 3 in rheumatoid arthritis.
    Xiu Z; Shen H; Tian Y; Xia L; Lu J
    Cytokine; 2015 Apr; 72(2):185-9. PubMed ID: 25647275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble TL1A is sufficient for activation of death receptor 3.
    Bittner S; Knoll G; Füllsack S; Kurz M; Wajant H; Ehrenschwender M
    FEBS J; 2016 Jan; 283(2):323-36. PubMed ID: 26509650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-TL1A monoclonal antibody modulates the dysregulation of Th1/Th17 cells and attenuates granuloma formation in sarcoidosis by inhibiting the PI3K/AKT signaling pathway.
    Ma C; Huang J; Zheng Y; Na Y; Wei J; Shan J; Meng K; Zhang X; Zhang S; Wen Y; Ding J
    Int Immunopharmacol; 2024 Aug; 137():112360. PubMed ID: 38852524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.